DeCure for Ehlers-Danlos syndrome, hypermobility type
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Ehlers-Danlos syndrome, hypermobility type — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEhlers-Danlos syndrome, hypermobility type maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ehlers-danlos syndrome, hypermobility type is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
collagen type III alpha 1 chain (COL3A1) — COL3A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet flcdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6FZW · 2.78 Å · ligand CITRATE ANION (FLC). Experimental structure, not a prediction.
What the evidence adds up to
Hypermobile Ehlers-Danlos syndrome is the only subtype among the 13 recognised Ehlers-Danlos syndromes that has no known genetic cause. The 2017 international classification delineates 13 clinical subtypes, each with major and minor diagnostic criteria, but for hypermobile EDS patients are identified solely through clinical diagnosis guidelines meant to differentiate it from other hypermobile joint conditions and EDS subtypes. A 2018 review notes that efforts on recognition, diagnosis, and management have been an ongoing challenge even decades after the condition was first described, and that the revised classification brought significant attention to this often underappreciated condition. The leading symptoms across the EDS group are joint hypermobility, skin hyperextensibility, and generalised tissue fragility; certain subtypes affect only quality of life, while others can lead to severe or fatal vascular or intestinal complications.
A 2022 case report describes the first published full hospital course of a patient with hypermobility syndrome–comorbidity-related complications, emphasising that systemic differences resulting from hypermobility syndromes must be recognised in hospital settings to avoid harm. The condition may present alongside autonomic, neurologic, and immune abnormalities. A 2020 overview lists current treatment options and the clinical criteria guiding standard of care, but does not report any drug trial results or quantitative outcomes such as survival or response rates. A 2019 Hungarian review provides a table of complex, multidisciplinary symptoms to assist differential diagnosis, and states that proper diagnosis is essential to give optimal clinical care and prevent severe complications.
No abstract reports any controlled trial, any drug tested, or any quantitative measure of treatment effect in hypermobile EDS. The supplemental material for a 2022 study on health-related quality of life and psychological distress is referenced but its findings are not summarised in the provided text. What is still missing is any randomised trial of a pharmacological intervention, any validated biomarker or genetic target for the hypermobile subtype, and any stratification of patients by symptom cluster or comorbidity profile that could guide future study design. Funding for such trials and for the basic genetic work needed to identify a causative mutation remains absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Balkan Medical Journal · 2018 · 36 citations · open access
Updates in Clinical and Genetics Aspects of Hypermobile Ehlers Danlos Syndrome
AbstractEfforts on recognition, diagnosis, and management of the presumed, most common connective tissue disorder hypermobile Ehlers-Danlos syndrome have been an ongoing challenge, even decades after the description of this condition. A recent international consortium proposed a revised Ehlers-Danlos syndrome classification, an update much needed since Villefranche nosology, in 1998. Hypermobile Ehlers-Danlos syndrome is the only subtype in these groups of syndromes with no known genetic cause(s). This effort brought significant attention to this often underappreciated condition. This review provides an update of the clinical and genetic aspects of hypermobile Ehlers-Danlos syndrome for clinicians and researchers.
Journal of Osteopathic Medicine · 2020 · 32 citations
The Many Facets of Hypermobile Ehlers-Danlos Syndrome
AbstractOf the 13 subtypes of Ehlers-Danlos Syndromes (EDSs) identified in the 2017 international classification of EDSs, 12 have a recognized, associated genetic mutation. However, hypermobile EDS (hEDS) currently has no identifiable associated gene. Therefore, patients with hEDS are identified through a set of clinical diagnosis guidelines and criteria, which are meant to differentiate hEDS from other hypermobile joint conditions and other EDSs subtypes. In this article, the authors provide an overview of hEDS symptoms and comborbidities, current treatment options, and the clinical criteria currently guiding the standard of care.
Az Ehlers–Danlos-szindrómák korszerű osztályozása és multidiszciplináris tünettana
AbstractIn this review article, the authors summarize the clinical aspects of the novel classification of Ehlers-Danlos syndrome, which is a group of rare, hereditary connective tissue disorders. The leading symptom of the Ehlers-Danlos syndrome group is joint hypermobility, skin hyperextensibility and generalized tissue fragility. Ehlers-Danlos syndrome displays a high clinical and genetic heterogeneity and harbors many multidisciplinary properties. Certain subtypes only affect the quality of life, while other forms may lead to severe, even fatal vascular or intestinal complications. Last year, based on the data of various international genotype-phenotype correlation studies of large populations, a new classification of the syndrome's clinical subtypes was introduced. The novel international nosology of Ehlers-Danlos syndromes published in 2017 delineates 13 clinical subtypes, describes their genetic background and defines major and minor diagnostic criteria for each subtype. We gathered the complex, multidisciplinary symptoms of Ehlers-Danlos syndromes in a table to assist the diagnosis from a differential diagnostic point of view. In the clinical practice, the proper diagnosis of patients affected by the Ehlers-Danlos syndrome group is essential to give optimal clinical care and to prevent the development of severe complications. Orv Hetil. 2019; 160(16): 603-612.
Sage Journals Data · 2022 · 0 citations · open access
sj-docx-1-sgo-10.1177_21582440221091237 – Supplemental material for Health-Related Quality of Life and Psychological Distress in Patients With Hypermobility Type Ehlers-Danlos Syndrome
AbstractSupplemental material, sj-docx-1-sgo-10.1177_21582440221091237 for Health-Related Quality of Life and Psychological Distress in Patients With Hypermobility Type Ehlers-Danlos Syndrome by Orenius Tage, Kautiainen Hannu, Louhi Marja, Montin Liisa, Bulbena Antonio and Lindgren Karl-August in SAGE Open
Annals of Internal Medicine Clinical Cases · 2022 · 0 citations · open access
Hospital Stay Considerations in Hypermobile Ehlers-Danlos Syndrome: An Exemplary Case With Insights for Coexisting Symptoms
AbstractEhlers-Danlos syndrome, hypermobility type, is a complex medical condition understood to be a genetic disorder resulting in abnormal collagen synthesis. It is characterized by joint hypermobility as well as skin laxity, poor wound healing, and other manifestations. It may present in conjunction with autonomic, neurologic, and immune abnormalities. Hypermobility spectrum disorder is similarly characterized by joint hypermobility but holds less extensive diagnostic criteria. When in the hospital setting, systemic differences resulting from hypermobility syndromes must be recognized to avoid harm. Here, we present the first case, to our knowledge, of a full hospital course with hypermobility syndrome–comorbidity-related complications described.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
